

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-57. (Canceled)

58. (New) A peptide which sensitizes cells for apoptosis comprising:

- (a) the amino acid sequence of SEQ ID NO: 127; or
- (b) an amino acid sequence at least 90% identical to SEQ ID NO: 127 and which is capable of binding to livin- β .

59. (New) A composition comprising the peptide of claim 58 linked to a carrier which mediates the uptake of the peptide into a cell.

60. (New) A method of sensitizing a livin- β -expressing cell for apoptosis, comprising administering to a livin- β -expressing cell the peptide of claim 58, optionally in combination with an intercalating agent, wherein said peptide binds to livin- β in said cell, and wherein said binding of peptide to livin- β sensitizes said cell for apoptosis.

61. (New) The method of claim 60, wherein said cell is a cancer cell.

62. (New) The method of claim 61, wherein said cancer cell is a melanoma cell.

63. (New) A pharmaceutical composition for the treatment of cancer, comprising the peptide of claim 58 and a pharmaceutically-acceptable carrier, optionally in combination with an intercalating agent.

64. (New) A diagnostic kit for the detection of livin- β in cancer cells, comprising the peptide of claim 58 and a buffer.